(+)-(3aR,4R,5r,6aS)-六氢-5-羟基-4-[(1E,3R)-3-羟基-4-(3-三氟甲基)苯氧基-1-丁烯基]-2H-环戊并[b]呋喃-2-酮 | 53872-60-9

• 物质功能分类: 生物 - 生化试剂盒
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (+)-(3aR,4R,5r,6aS)-六氢-5-羟基-4-[(1E,3R)-3-羟基-4-(3-三氟甲基)苯氧基-1-丁烯基]-2H-环戊并[b]呋喃-2-酮
• 中文别名: 曲沃前列素中间体；2H-环戊并[b]呋喃-2-酮,六氢-5-羟基-4-[(1E,3R)-3-羟基-4-[3-(三氟甲基)苯氧基]-1-丁烯-1-基]-,(3aR,4R,5R,6aS)-；(+)-(3AR,4R,5R,6AS)-六氢-5-羟基-4-[(1E,3R)-3-羟基-4-(3-三氟甲基)苯氧基-1-丁烯基]-2H-环戊并[B]呋喃-2-酮；2H-环戊并[B]呋喃-2-酮,六氢-5-羟基-4-[(1E,3R)-3-羟基-4-[3-(三氟甲基)苯氧基]-1-丁烯-1-基]-,(3AR,4R,5R,6AS)-；2H-环戊并[b]呋喃-2-酮,六氢-5-羟基-4-[(1E,3R)-3-羟基-4-[3-(三氟甲基)苯氧基]-1-丁烯-1-基]-, (3aR,4R,5R,6aS)-
• 英文名称: (3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]-hexahydro-2H-cyclopenta[b]furan-2-one
• 英文别名: (3aR,4R,5R,6aS)-5-hydroxy-4-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one；(3aR,4R,5R,6aS)-4-((3R,E)-4-(3-(trifluoromethyl)phenoxy)-3-hydroxybut-1-enyl)-hexahydro-5-hydroxycyclopenta[b]furan-2-one；(3aR,4R,5R,6aS)-4-((R,E)-4-(3-(trifluoromethyl)phenoxy)-3-hydroxybut-1-enyl)-hexahydro-5-hydroxycyclopenta[b]furan-2-one；(3aR,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[β]furan-2-one；(3aR,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(3R)-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[β]furan-2-one；(3aR,4R,5R,6aS)-5-hydroxy-4-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)hexahydro-2H-cyclopenta[b]furan-2-one；(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one
• CAS: 53872-60-9
• 化学式: C₁₈H₁₉F₃O₅
• 分子量: 372.341
• InChiKey: XYSPYIAAWRUEML-AVMWIMHJSA-N

物化性质

• 沸点：
  520.6±50.0 °C(Predicted)
• 密度：
  1.433±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：25mg/mL； DMF:PBS (pH 7.2) (1:10)：100 μg/ml； DMSO：17mg/mL；乙醇：20mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (+)-(3aR,4R,5r,6aS)-六氢-5-羟基-4-[(1E,3R)-3-羟基-4-(3-三氟甲基)苯氧基-1-丁烯基]-2H-环戊并[b]呋喃-2-酮 在 sodium methylsulfinylcarbanide 、 二异丁基氢化铝 、 对甲苯磺酸 作用下， 以 正己烷 、 二氯甲烷 、 甲苯 为溶剂， 反应 2.83h， 生成
  参考文献：
  名称：

  N-(Methanesulfonyl)-16-phenoxyprostaglandin carboxamides: tissue-selective, uterine stimulants

  摘要：

  In an effort to develop tissue-selective prostaglandin analogues resistant to the metabolic inactivating pathways of the natural materials, hybrid compounds modified both at C-1 with a sulfonimide moiety and in the n-amylcarbinol side chain with substituted phenoxy groups were synthesized and evaluated in a variety of in vitro models. Several of these analogues exhibited potent, tissue-selective, uterine stimulant activity, a finding subsequently confirmed in clinical studies with one member of this series, N-(methanesulfonyl)-16-phenoxy-omega-tetranor-PGE2-carboxamide (CP-34089/ZK-57671, sulprostone).

  DOI：

  10.1021/jm00143a018
• 作为产物：
  描述：

  (3aR,4S,5R,6aS)-(-)-六氢-4-(羟甲基)-2-氧代-2H-环戊并[b]呋喃-5-基 1,1'-联苯-4-甲酸酯 在 4-二甲氨基吡啶 、 potassium tert-butylate 、 potassium carbonate 、 戴斯-马丁氧化剂 、 三乙胺 、 (-)-diisopinocamphenylborane chloride 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 (+)-(3aR,4R,5r,6aS)-六氢-5-羟基-4-[(1E,3R)-3-羟基-4-(3-三氟甲基)苯氧基-1-丁烯基]-2H-环戊并[b]呋喃-2-酮
  参考文献：
  名称：

  [EN] AN IMPROVED AND SCALABLE PROCESS FOR PREPARATION OF PROSTAGLANDIN DERIVATIVES AND INTERMEDIATES THEREOF
  [FR] TRAITEMENT AMÉLIORÉ ET ÉVOLUTIF DE PRÉPARATION DE DÉRIVÉS DE PROSTAGLANDINE ET DE LEURS INTERMÉDIAIRES

  摘要：

  本文提供了一种改进的、具有商业可行性和工业优势的过程，用于制备前列腺素衍生物及其中间体，产率高且纯度高。

  公开号：

  WO2013164729A1

文献信息

• Processes and intermediates for the preparations of prostaglandins
  申请人：Wei Shih-Yi

  公开号：US20070167641A1

  公开（公告）日：2007-07-19

  The present invention provides novel processes for the preparation of a cyclopentanone of Formula II and a lactone of Formula I, which are useful in the production of prostaglandins: wherein Z, R 2 , R 3 , X 1 , X 2 , and are as defined in the specification. The invention also provides novel enantiomerically enriched compounds.

  本发明提供了一种用于制备化合物II的环戊酮和化合物I的内酯的新型工艺，这些化合物在前列腺素的生产中很有用：其中Z、R2、R3、X1、X2和如规范中所定义的。该发明还提供了新型对映富集化合物。
• PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS
  申请人：CHIROGATE INTERNATIONAL INC.

  公开号：US20150051410A1

  公开（公告）日：2015-02-19

  Novel processes for the preparation of a compound of Formula I-2 substantially free of the 5,6-trans isomer: wherein R 2 , R 3 and R 4 are as defined in the specification are provided. Novel intermediates for the preparations of isomer free Prostaglandins and derivatives thereof are also provided.

  提供了一种用于制备基本上不含5,6-顺式异构体的化合物I-2的新工艺：其中R2、R3和R4如规范中定义。还提供了用于制备无异构体前列腺素及其衍生物的新中间体。
• [EN] PROCESS FOR THE PREPARATION OF F-SERIES PROSTAGLANDINS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE PROSTAGLANDINES DE LA SÉRIE F
  申请人：CAYMAN CHEM CO

  公开号：WO2011046569A1

  公开（公告）日：2011-04-21

  A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the representative F-series prostaglandin compounds such as latanoprost, bimatoprost, fluprostenol, cloprostenol, and substituted analogs therefrom in highly pure forms.

  用于合成和纯化F系列前列腺素化合物和用于制备它们的合成中间体的过程。这些合成中间体是固体，可以通过沉淀纯化，因此可以形成代表性的F系列前列腺素化合物，如拉他诺前列醇、比马前列醇、氟前列醇、克洛前列醇以及其高度纯净的取代物。
• [EN] A NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF<br/>[FR] NOUVEAU PROCÉDÉ DE PRÉPARATION DE PROSTAGLANDINES ET DE LEURS INTERMÉDIAIRES
  申请人：BIOCON LTD

  公开号：WO2011055377A1

  公开（公告）日：2011-05-12

  This invention relates to novel process for the preparation of prostaglandin compounds having formula (K), wherein R is selected from the group consisting of C1-C7 alkyl; C7-C17 aralkyl wherein the aryl group is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl, halo and CF3; and (CH2)nOR2 wherein n is from 1 to 3 and R2 represents a C6-C10 aryl group which is unsubstituted or substituted with one to three substituents selected from the group consisting of C1-C6 alkyl, halo and CF3; and R1 is selected from OR3 and NHR3 wherein R3 is C1-C6 alkyl, H; and dashed lines represents a double bond or a single bond, is disclosed. Novel intermediates are also disclosed.

  本发明涉及一种制备公式（K）的前列腺素化合物的新工艺，其中R选自以下组中的一组：C1-C7烷基；C7-C17芳基烷基，其中芳基基团未取代或取代有1-3个取自C1-C6烷基，卤素和CF3的取代基；以及（CH2）nOR2，其中n为1-3，R2代表未取代或取代有1-3个取自C1-C6烷基，卤素和CF3的取代基的C6-C10芳基基团；R1选自OR3和NHR3，其中R3为C1-C6烷基，H；虚线表示双键或单键。本发明还揭示了新的中间体。
• NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF
  申请人：Aswathanarayanappa Chandrashekar

  公开号：US20120209011A1

  公开（公告）日：2012-08-16

  This invention relates to novel process for the preparation of prostaglandin compounds having formula (K), wherein R is selected from the group consisting of C 1 -C 7 alkyl; C 7 -C 17 aralkyl wherein the aryl group is unsubstituted or substituted with one to three substituents selected from the group consisting of C 1 -C 6 alkyl, halo and CF 3 ; and (CH 2 ) n OR 2 wherein n is from 1 to 3 and R 2 represents a C 6 -C 10 aryl group which is unsubstituted or substituted with one to three substituents selected from the group consisting of C 1 -C 6 alkyl, halo and CF 3 ; and R 1 is selected from OR 3 and NHR 3 wherein R 3 is C 1 -C 6 alkyl, H; and dashed lines represents a double bond or a single bond, is disclosed. Novel intermediates are also disclosed.

  本发明涉及一种新型的制备具有式（K）的前列腺素化合物的方法，其中R选自以下组中的一种：C1-C7烷基；C7-C17芳基烷基，其中芳基基团未取代或取代有1至3个取代基，所述取代基选自C1-C6烷基，卤素和CF3；以及（CH2）nOR2，其中n为1至3，R2代表未取代或取代有1至3个取代基的C6-C10芳基基团，所述取代基选自C1-C6烷基，卤素和CF3；R1选自OR3和NHR3，其中R3为C1-C6烷基，H；虚线表示双键或单键。本发明还公开了新型中间体。